Table 2 AR and ER results among the 290 ER-enriched breast cancer patients
AR stain | ER stain | Tamoxifen (n = 151) | Tamoxifen + Fluoxymesterone (n = 139) |
|---|---|---|---|
< 1% | 71–80 | 3 (2.0%) | 2 (1.4%) |
< 1% | 81–90 | 3 (2.0%) | 1 (0.7%) |
< 1% | 91–100 | 14 (9.2%) | 29 (20.9%) |
1–10 | 71–80 | 0 | 2 (1.4%) |
1–10 | 81–90 | 1 (0.7%) | 1 (0.7%) |
1–10 | 91–100 | 14 (9.3%) | 6 (4.3%) |
11–20 | 71–80 | 1 (0.7%) | 0 |
11–20 | 81–90 | 1 (0.7%) | 0 |
11–20 | 91–100 | 9 (6.0%) | 4 (2.9%) |
21–30 | 91–100 | 1 (0.7%) | 5 (3.6%) |
31–40 | 81–90 | 1 (0.7%) | 0 |
31–40 | 91–100 | 5 (3.3%) | 5 (3.6%) |
41–50 | 81–90 | 2 (1.3%) | 1 (0.7%) |
41–50 | 91–100 | 5 (3.3%) | 1 (0.7%) |
51–60 | 71–80 | 2 (1.3%) | 0 |
51–60 | 91–100 | 1 (0.7%) | 5 (3.6%) |
61–70 | 81–90 | 1 (0.7%) | 0 |
61–70 | 91–100 | 2 (1.3%) | 5 (3.6%) |
71–80 | 80–91 | 0 | 1 (0.7%) |
71–80 | 91–100 | 10 (6.6%) | 10 (7.2%) |
81–90 | 81–90 | 0 | 1 (0.7%) |
81–90 | 91–100 | 14 (9.3%) | 20 (14.4%) |
91–100 | 81–90 | 2 (1.3%) | 0 |
91–100 | 91–100 | 59 (39.1%) | 40 (28.8%) |